Mark W. Frampton, M.D.

Mark W. Frampton, M.D.

Contact Information

University of Rochester Medical Center
School of Medicine and Dentistry
601 Elmwood Ave, Box 692
Rochester, NY 14642

Office: (585) 275-4161
Fax: (585) 273-1171
Administrative: (585) 275-4861

Professional Bio

Dr. Mark Frampton is Professor of Medicine and Environmental Medicine in the Pulmonary and Critical Care Division at the University of Rochester School of Medicine. He received his MD from New York University School of Medicine and then trained in Internal Medicine at Buffalo General Hospital. After nine years of private practice in Williamson, New York, he completed Pulmonary and Critical Care training at the University of Rochester, and then joined the faculty. His primary research interest is the health effects of air pollution, and he directs an NIH-funded training program in pulmonary research.



Dr. Frampton directs the Pulmonary Function Laboratory at Strong Memorial Hospital. He has an active outpatient pulmonary clinic, seeing a broad spectrum of patients with pulmonary diseases, and also attends and teaches on the Pulmonary Consultation Service at Strong Memorial Hospital. He has a special interest in tuberculosis, having directed the Wayne County Tuberculosis Clinic for more than 30 years, and has been caring for patients with tuberculosis infection and disease at the Monroe County Health Department for more than 20 years.

Research Bio

Each day the average person breathes about 15,000 liters, or approximately 35 pounds, of air. Gaseous and particulate contaminants in that air gain access to the body with each breath, and may have both short and long-term effects on human health. Our ongoing studies examine the effects of particle exposure on lung function, airway inflammation, and cardiovascular function. Utilizing both environmental chamber and mouthpiece exposure systems, subjects are exposed to environmentally relevant concentrations of pollutants, with or without exercise. Respiratory and systemic effects are determined using measures of lung function, examination for markers of inflammation in exhaled air, characterization of blood leukocyte and platelet responses using 3-color flow cytometry, and detailed cardiovascular monitoring.



Ultrafine particles (UFP, <100 nm diameter) may be particularly important with regard to cardiovascular effects because of their potential for evading clearance mechanisms and entering the lung interstitium and vascular space. We have demonstrated in healthy nonsmokers that inhalation of low concentrations of UFP causes changes in leukocyte expression of adhesion molecules, and reductions in the pulmonary diffusing capacity, that are consistent with altered endothelial function. The elderly and people with underlying vascular disease, such as diabetics, may be more susceptible to vascular effects of particle exposure because of impaired endothelial function and increased risk for atherosclerosis. Our studies explore the hypothesis that inhalation of ultrafine particles alters endothelial function in healthy and susceptible people. Endothelial dysfunction is critically linked to the pathogenesis of atherosclerotic vascular disease. Data from these human clinical studies of exposure to air pollutants help to elucidate the mechanisms responsible for pollutant health effects, and assist in establishing rational air quality standards.

Awards & Honors (Local)

Fellow, American College of Physicians 1974 - Present

Recent Journal Articles

Showing the 5 most recent journal articles. 98 available »

2014 Jul 16
Vora R, Zareba W, Utell MJ, Pietropaoli AP, Chalupa D, Little EL, Oakes D, Bausch J, Wiltshire J, Frampton MW. "Inhalation of ultrafine carbon particles alters heart rate and heart rate variability in people with type 2 diabetes." Particle and fibre toxicology. 2014 Jul 16; 11(1):31. Epub 2014 Jul 16.
2012 Oct
Frampton MW, Bausch J, Chalupa D, Hopke PK, Little EL, Oakes D, Stewart JC, Utell MJ. "Effects of outdoor air pollutants on platelet activation in people with type 2 diabetes." Inhalation toxicology.. 2012 Oct; 24(12):831-8.
2012 Aug
Rich DQ, Zareba W, Beckett W, Hopke PK, Oakes D, Frampton MW, Bisognano J, Chalupa D, Bausch J, O'Shea K, Wang Y, Utell MJ. "Are ambient ultrafine, accumulation mode, and fine particles associated with adverse cardiac responses in patients undergoing cardiac rehabilitation?" Environmental health perspectives.. 2012 Aug; 120(8):1162-9. Epub 2012 Apr 27.
2011 Jul 15
Frampton MW. "Ozone air pollution: how low can you go?" American journal of respiratory and critical care medicine.. 2011 Jul 15; 184(2):150-1.
2011 Jun
Gough MS, Morgan MA, Mack CM, Darling DC, Frasier LM, Doolin KP, Apostolakos MJ, Stewart JC, Graves BT, Arning E, Bottiglieri T, Mooney RA, Frampton MW, Pietropaoli AP. "The ratio of arginine to dimethylarginines is reduced and predicts outcomes in patients with severe sepsis." Critical care medicine.. 2011 Jun; 39(6):1351-8.

Current Appointments

Professor Emeritus - Department of Medicine, Pulmonary Diseases and Critical Care (SMD) - Primary

Specialties

Pulmonary Disease - American Board of Internal Medicine
Critical Care Medicine - American Board of Internal Medicine
Internal Medicine - American Board of Internal Medicine

Education

MD | Medicine | New York Univ Sch Medicine1973
Mathematics, Microbiology | California State University, Long BeachAttended 1965 - 1969

Post-Doctoral Training & Residency

Fellowship in Pulmonary & Critical Care at Strong Memorial Hospital- GME Office07/01/1985 - 06/30/1988
Residency in Internal Medicine at Buffalo General Hospital07/01/1974 - 06/30/1976
Internship in Internal Medicine at Buffalo General Hospital07/01/1973 - 06/30/1974